Xiaobing Li, Meipan Yin, Pengfei Xie, Yue Zhao, Ying Liu, Xiangnan Li, Yu Qi, Yaozhen Ma, Chunxia Li, Gang Wu
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Respiratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Clin Lung Cancer. 2022 May;23(3):e203-e209. doi: 10.1016/j.cllc.2021.10.011. Epub 2021 Oct 29.
To evaluate the safety and effectiveness of bronchial arterial infusion chemoembolization (BAICE) for lung cancer with hemoptysis.
Retrospectively analyze clinical data of patients undergoing BAICE for the treatment of lung cancer with hemoptysis, evaluate the clinical efficacy of this approach, observe postoperative adverse reactions, and analyze hemoptysis-free survival (HFS) and overall survival (OS).
All 187 patients underwent BAICE with technical success rate of 100%, clinical success rate of 86.6%, clinical failure rate of 13.4%. After BAICE, the tumor curative effect was evaluated as complete remission in 56 cases, partial remission in 82 cases, stable disease in 26 cases, and progressive disease in 6 cases. The objective response rate was 73.8%, and the disease control rate was 87.7%. Median HFS of the 154 clinically successful cases was 10.5 months (95% confidence interval [CI]: 8.11-11.89). The degree of hemoptysis (massive hemoptysis hazard ratio [HR] = 5.9, 95% CI: 3.43-10.16, P = .00) and cavitary lung mass (HR = 2.39, 95% CI: 1.44-3.99, P = .001), were significantly related to a reduction in HFS after BAICE. The 6-month and 12-month survival rates were 66.5% and 45.6%, respectively. The median OS of clinically successful cases was 13.0 months (95% CI: 11.22-14.77). The median OS of 16 clinically failed cases was 2.0 months (95% CI: 0.41-2.45) (P < .001). All adverse events were grade 1.
BAICE for advanced lung cancer with hemoptysis is safe, effective, and tolerable.
评估支气管动脉灌注化疗栓塞术（BAICE）治疗肺癌咯血的安全性和有效性。
回顾性分析接受BAICE治疗肺癌咯血患者的临床资料，评估该方法的临床疗效，观察术后不良反应，并分析无咯血生存期（HFS）和总生存期（OS）。
187例患者均接受BAICE治疗，技术成功率为100%，临床成功率为86.6%，临床失败率为13.4%。BAICE术后，肿瘤疗效评估为完全缓解56例，部分缓解82例，病情稳定26例，病情进展6例。客观缓解率为73.8%，疾病控制率为87.7%。154例临床成功病例的中位HFS为10.5个月（95%置信区间[CI]：8.11 - 11.89）。咯血程度（大量咯血风险比[HR] = 5.9，95% CI：3.43 - 10.16，P = .00）和肺空洞性肿块（HR = 2.39，95% CI：1.44 - 3.99，P = .001）与BAICE术后HFS缩短显著相关。6个月和12个月生存率分别为66.5%和45.6%。临床成功病例的中位OS为13.0个月（95% CI：11.22 - 14.77）。16例临床失败病例的中位OS为2.0个月（95% CI：0.41 - 2.45）（P < .001）。所有不良事件均为1级。
BAICE治疗晚期肺癌咯血安全、有效且可耐受。
